

DESCRIPTION

Species Reactivity	Human
Specificity	Detects human OSM R β in direct ELISAs and Western blots. In direct ELISAs and Western blots, no cross-reactivity with recombinant mouse OSM R β is observed.
Source	Monoclonal Mouse IgG ₁ Clone # 469221
Purification	Protein A or G purified from hybridoma culture supernatant
Immunogen	Mouse myeloma cell line NS0-derived recombinant human OSM R β Glu28-Ser739 Accession # Q99650
Conjugate	Alexa Fluor 405 Excitation Wavelength: 405 nm Emission Wavelength: 421 nm
Formulation	Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide. See Certificate of Analysis for details. *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. [General Protocols](#) are available in the [Technical Information](#) section on our website.

	Recommended Concentration	Sample
Flow Cytometry	0.25-1 μ g/10 ⁶ cells	HeLa human cervical epithelial carcinoma cell line

PREPARATION AND STORAGE

Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied.

BACKGROUND

OSM R β is a 150-180 kDa member of the IL-6 receptor family. It associates with gp130 to form the type II OSM receptor that is responsive to OSM. The gp130 subunit is shared by other IL-6 family cytokine receptors (1, 2, 3, 4), and OSM R β associates with gp130-like receptor (GPL) to form a receptor complex responsive to IL-31 (5, 6). The human OSM R β cDNA encodes a 979 amino acid (aa) precursor that includes a 27 aa signal sequence, a 712 aa extracellular domain (ECD), a 22 aa transmembrane segment, and a 218 aa cytoplasmic domain. The ECD contains one partial and one complete hematopoietin domain, an Ig-like domain, and three fibronectin type-III domains. The cytoplasmic domain contains box1, 2, and 3 motifs (7). Within the ECD, human OSM R β shares 55%, 58%, 61%, and 72% aa sequence identity with mouse, rat, bovine, and canine OSM R β , respectively. It also shares 31% aa sequence identity with human LIF R, but less than 20% aa sequence identity with human CNTF R α , G-CSF R, IL-6 R, IL-11 R α , and TCCR. OSM R β does not bind cytokines directly, but increases the affinity of gp130 for OSM, and GPL for IL-31 (7, 8). OSM R β , gp130, and GPL each initiate signaling events following ligand stimulation (9, 10). Jak/STAT and MAPK pathways are activated by OSM R β -containing receptors (9, 11, 12, 13), including STAT5b and SHC which are not activated by other IL-6 family receptors (10, 13). In mice, the loss of OSM R β expression blocks erythroid progenitor development in bone marrow, and dramatically reduces the number of circulating platelets and erythrocytes (14). The type II OSM receptor is the only IL-6 family receptor that promotes osteoblast differentiation in calvaria cell cultures (15).

References:

- Chen, S.-H. and E.N. Benveniste (2004) Cytokine Growth Factor Rev. **15**:379.
- Heinrich, P.C. *et al.* (2003) Biochem. J. **374**:1.
- Tanaka, M. and A. Miyajima (2003) Rev. Physiol. Biochem. Pharmacol. **149**:39.
- Gearing, D.P. *et al.* (1992) Science **255**:1434.
- Dillon, S.R. *et al.* (2004) Nat. Immunol. **5**:752.
- Diveu, C. *et al.* (2003) J. Biol. Chem. **278**:49850.
- Mosley, B. *et al.* (1996) J. Biol. Chem. **271**:32635.
- Diveu, C. *et al.* (2004) Eur. Cytokine Netw. **15**:291.
- Dreuw, A. *et al.* (2004) J. Biol. Chem. **279**:36112.
- Wang, Y. *et al.* (2000) J. Biol. Chem. **275**:25273.
- Hermanns, H.M. *et al.* (2000) J. Biol. Chem. **275**:40742.
- Kuropatwinski, K.K. *et al.* (1997) J. Biol. Chem. **272**:15135.
- Auguste, P. *et al.* (1997) J. Biol. Chem. **272**:15760.
- Tanaka, M. *et al.* (2003) Blood **102**:3154.
- Malaval, L. *et al.* (2005) J. Cell. Physiol. **204**:585.

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.